A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study

The Phase 3 study found a drug didn’t reduce the risk of cardiovascular events like heart attacks and strokes.

Discover more from RealUS.news